Alzamend Neuro Inc. (ALZN)
NASDAQ: ALZN
· Real-Time Price · USD
2.33
-0.01 (-0.43%)
At close: Aug 20, 2025, 11:01 AM
-0.43% (1D)
| Bid | 2.31 |
| Market Cap | 6.75M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -4.51M |
| EPS (ttm) | -101.88 |
| PE Ratio (ttm) | -0.02 |
| Forward PE | -0.15 |
| Analyst | Buy |
| Ask | 2.38 |
| Volume | 16,445 |
| Avg. Volume (20D) | 1,594,933 |
| Open | 2.30 |
| Previous Close | 2.34 |
| Day's Range | 2.30 - 2.37 |
| 52-Week Range | 2.06 - 47.70 |
| Beta | -0.32 |
About ALZN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ALZN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ALZN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
-29.6%
Alzamend Neuro shares are trading lower. The stock...
Unlock content with
Pro Subscription
2 months ago
+63.86%
Alzamend Neuro shares are trading higher after the company dosed the first patient in its Phase II clinical trial of AL001.
